Schizophrenics p < 0.001
Figure 4.4 The effect of amphetamine (0.3 mg/kg) on [123I]IBZM binding in healthy control subjects and untreated patients with schizophrenia. [123I]IBZM is a tracer for D2 receptors which allows in vivo measurement of D2 receptor availability (or binding potential) in humans using single photon emission tomography (SPET). The y-axis shows the percentage decrease in [123I]IBZM binding potential induced by amphetamine, which is a measure of the increased occupancy of D2 receptors by dopamine following the challenge. Thus, these results indicate that, when challenged with amphetamine, patients with schizophrenia release more dopamine than do healthy controls. Figure reproduced with permission from Laruelle M, Abi-Dargham A, Gil R, et al. Increased dopamine transmission in schizophrenia: relationship to illness phases [Review]. Biol Psychiatry 1999; 46:56-72
Was this article helpful?